Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Phillip Strauss"'
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Introduction: The research objective was to systematically review evidence on neurotrophic tyrosine receptor kinase ( NTRK ) gene fusion frequency in solid tumors. Methods: Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRI
Externí odkaz:
https://doaj.org/article/54510360fb6f4c01b6b86848a774c6a0
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Introduction: The research objective was to systematically review evidence on neurotrophic tyrosine receptor kinase ( NTRK) gene fusion frequency in solid tumors. Methods: Using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRIS
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Proceedings of the 6th Unconventional Resources Technology Conference.
Autor:
Camillo Porta, Tomasz Demkow, Alessandra Bearz, Martin Gore, Jo Ann Shapiro, Robert Jones, Alain Ravaud, Uwe Phillip Strauss, Markus A. Kuczyk
Objective: \ud \ud To assess the efficacy and safety of sorafenib dose escalation in metastatic renal cell carcinoma (mRCC).\ud Patients and Methods: \ud \ud Intra-patient dose escalation may enhance the clinical benefit of targeted anticancer agents
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b164caf0a3105d8373b3646cb0ded14f
https://eprints.gla.ac.uk/133349/1/133349.pdf
https://eprints.gla.ac.uk/133349/1/133349.pdf
Autor:
Markus Langen, Uwe Phillip Strauss, Holger Schulz, Jan Janssen, Marcel Frey, Sabine Fiala-Buskies, Carsten Bokemeyer
Publikováno v:
Journal of Clinical Oncology. 35:769-769
769 Background: In 2013 REG was approved for mCRC based on the results achieved in the CORRECT trial. However, prospective data from daily practice use are still scarce. Methods: RECORA is investigating efficacy and safety of REG in routine clinical
Autor:
Vincente Alberola, Uwe Phillip Strauss, David F. Heigener, Bonne Biesma, Etienne Le Marie, Yan Sun, Elaine Montegriffo, Luis Paz-Ares, Timothy Eisen, Jaafar Bennouna, Armando Santoro, Teng Jin Ong, Joachim von Pawel, Steven Gans, Meilin Liao, Johan Vansteenkiste, Kostas N. Syrigos, Maya Gottfried, Li Zhang
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(25)
Purpose This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non–small-cell lung cancer (NSCLC). Patients and Methods Between February 200
Publikováno v:
Clinical drug investigation. 23(6)
Objective: The aim of this multicentre, double-blind, vehicle-controlled study was to investigate the safety and efficacy of once-daily topical application of sertaconazole 2% cream compared with corresponding vehicle cream in the treatment of patien
Publikováno v:
American journal of clinical dermatology. 7(4)
Sertaconazole, an imidazole antifungal drug, has been proven to have broad and potent antifungal activity. In the present study, the pharmacokinetics of sertaconazole nail patches, developed for treatment of onychodystrophy and onychomycosis, were in
Publikováno v:
Arzneimittel-Forschung. 55(6)
The purpose of this open study was to evaluate the rate and extent of the penetration of sertaconazole nitrate (CAS 99592-32-2, Zalain ® ) penetration into the stratum corneum/lucidum of the human skin. Selected areas of 9 cm2 each of the back skin